Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study by Rodrigues, Junia et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Seroprevalence and factors associated with herpes simplex virus 
type 2 among HIV-negative high-risk men who have sex with men 
from Rio de Janeiro, Brazil: a cross-sectional study
Junia Rodrigues1, Beatriz Grinsztejn*1, Francisco I Bastos2, 
Luciane Velasque1, Paula M Luz1, Claudia TV de Souza1, Ingebourg Georg1, 
Jose H Pilotto1 and Valdilea G Veloso1
Address: 1Instituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Rio de Janeiro, Brazil and 2Instituto de Comunicação e 
Informação Científica e Tecnológica em Saúde (ICICT), Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
Email: Junia Rodrigues - junia.rodrigues@gmail.com; Beatriz Grinsztejn* - gbeatriz@ipec.fiocruz.br; 
Francisco I Bastos - chicao29@hotmail.com; Luciane Velasque - velasque@fiocruz.br; Paula M Luz - paula.luz@ipec.fiocruz.br; Claudia TV de 
Souza - clau@cpqhec.fiocruz.br; Ingebourg Georg - inge@ipec.fiocruz.br; Jose H Pilotto - jose.pilotto@ipec.fiocruz.br; 
Valdilea G Veloso - vgveloso@ipec.fiocruz.br
* Corresponding author    
Abstract
Background: Herpes simplex virus type 2 (HSV-2) is the leading cause of genital ulcer disease in
developing countries, including Brazil, and is especially prevalent among men who have sex with
men (MSM). HSV-2 infection represents a risk factor for the acquisition and transmission of other
sexually transmitted diseases. The goal of the present cross-sectional study was to estimate HSV-
2 seroprevalence and to determine the factors associated with HSV-2 seropositivity in HIV-
negative high-risk MSM from Rio de Janeiro, Brazil.
Methods: Stored sera were tested to estimate HSV-2 seroprevalence, while socio-demographic
and sexual behavior data were used to measure associations between risk factors and HSV-2
seropositivity. Using the Poisson regression model with robust variance, prevalence ratios (PR)
were used to estimate de degree of association between risk factors and HSV-2 seropositivity in
bivariate and multivariate analyses.
Results: Seroprevalence of HSV-2 was of 45.7% (184 out of 403). Factors independently associated
with HSV-2 seroprevalence in the multivariate model were: older age (≥ 26 years, PR: 1.41 95%
Confidence Interval: 1.11–1.78), non-white race (PR: 1.32 95%CI: 1.06–1.64), positive serology for
syphilis (PR: 1.65 95%CI: 1.33–2.05), positive serology for hepatitis B (PR: 1.25 95%CI: 0.99–1.57),
stable male partner in the past 6 months (PR: 1.42 95%CI: 1.12–1.79), and unprotected anal sex
with a stable female partner (PR: 1.46 95%CI: 1.05–2.04) in the 6 months preceding the cross-
sectional assessment.
Conclusion: The present study made evident a high prevalence of HSV-2 infection in a sample of
HIV-negative high-risk MSM from Rio de Janeiro. This finding indicates the need and urgency for
implementing integrated programs for the prevention of HSV-2 and other sexually transmitted
diseases, and, in particular, programs targeting high-risk MSM.
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Background
Herpes simplex virus type 2 (HSV-2) is the leading cause
of genital ulcer disease worldwide, and the main etiologi-
cal agent of genital herpes [1-3]. Although HSV-2 causes
anal-genital vesicles and ulcers that can be severe and
recurrent, most infections are asymptomatic with inter-
mittent genital excretion of the virus [4-6]. Transmission
of HSV-2 to a sexual partner occurs within the whole clin-
ical spectrum of this infection, i.e., in the presence of clin-
ical manifestations, during subclinical episodes and even
during periods of asymptomatic virus excretion [7,8].
HSV-2 is most frequently transmitted through the contact
with skin or mucosal lesions, or through genital or oral
secretions. Although contact with ulcerated lesions is the
most common route of transmission, contact with asymp-
tomatic patients can also lead to virus transmission
[6,8,9].
HSV-2 infection represents a risk factor for the acquisition
and transmission of other sexually transmitted diseases
(STDs) [3,10-12]. Observational epidemiological studies
have shown that HSV-2 facilitates the acquisition and
transmission of human immunodeficiency virus (HIV), a
fact that indicates the relevance of the pathogenesis and
epidemiology of HSV-2 [2,5,13-16]. Despite its impor-
tance, data on the seroprevalence of HSV-2 in different
populations are still limited when compared to other
STDs, especially in developing countries. Most published
data are derived from female populations or from patients
seen at STD clinics which are considered to be at higher
risk of infection with HSV-2 than the general population
[17]. Among men who have sex with men (MSM),
reported seroprevalences of HSV-2 vary as a function of
HIV status: high (80%) seroprevalences are observed
among those co-infected with HIV [18,19] while lower
(20%–50%) seroprevalences are reported for those not
infected with HIV [20-23].
Significant progress in the understanding of HSV-2 infec-
tion has occurred due to the development of highly sensi-
tive and specific serological tests (for the detection of HSV
type-specific antibodies) [4]. These tests permit the identi-
fication of antibodies specific to HSV-2 [2]. The goal of the
present cross-sectional study was to estimate HSV-2 sero-
prevalence and to determine the factors associated with
HSV-2 seropositivity among HIV-negative high-risk MSM
from Rio de Janeiro, Brazil.
Methods
Study population and study design
A total of 1165 MSM were interviewed at the Evandro
Chagas Clinical Research Institute (IPEC), Oswaldo Cruz
Foundation, Rio de Janeiro, between January 1994 and
December 1998, to evaluate eligibility to the open cohort
of HIV-negative individuals ('Projeto Rio', [24]). Cohort
eligibility criteria were men aged from 18 to 50 years who
engaged in sexual activity with other men and who were
HIV-negative at enrollment [25]. 'Projeto Rio' was con-
ceived to estimate important epidemiological measure-
ments, including HIV prevalence and incidence rates, and
to prepare local infrastructure for future HIV/STD inter-
ventions [24]. The project was funded by the World
Health Organization (WHO), the United Nations Joint
Program on AIDS (UNAIDS), and the Brazilian Ministry
of Health. Additional information on cohort's methods,
procedures and aims are available elsewhere [24]. Several
studies have been published on data generated through
'Projeto Rio', including HIV incidence rates [25], risk
behavior and perception of HIV vulnerability [26], illicit
drug use [27], and willingness to participate in HIV vac-
cine trials [28].
A total of 647 MSM met the eligibility criteria of 'Projeto
Rio' thus effectively enrolling in the cohort. At study entry,
participants had a blood sample drawn (for HIV, hepatitis
B and syphilis testing) and responded to a social and
behavioral questionnaire which was administered by a
trained psychologist [24]. The present study evaluated
HSV-2 seroprevalence for the 403 MSM who first enrolled
in 'Projeto Rio'.
Laboratory procedures
The 403 serum samples obtained at enrollment and
stored frozen at the Laboratory of Immunology of IPEC
(the original serum bank of 'Projeto Rio') were analyzed
by enzyme-linked immunosorbent assay (ELISA) for the
detection of IgG class antibodies to HSV-2 glycoprotein
G2 (HerpeSelect, Focus Technologies, Cypress, CA). HSV-
2 seropositivity was defined by a reactive ELISA with an
index ratio ≥ 3.5 in order to increase the specificity of the
assay [29-31].
Syphilis testing was performed using two serological
assays: the Venereal Disease Research Laboratory (VDRL)
test and the Treponema pallidum hemagglutination assay
(TPHA). Using both assays, two variables were defined:
(1) active syphilis when antibody titer with the VDRL test
was ≥ 1/8 and the TPHA was positive, and (2) positive
serology for syphilis when the VDRL test was not reactive
or < 1/8 and TPHA was positive. Positive serology for hep-
atitis B was assessed by the detection of antibodies to the
hepatitis B core antigen (anti-HBC) indicating previous
infection.
Statistical analyses
Factors potentially associated with HSV-2 seropositivity
were explored including covariates and confounders pre-
viously identified as being related to HSV-2 seropositivity
among MSM. Due to the high prevalence of HSV-2 among
participants prevalence ratios (PR) were used to estimate
the degree of association between HSV-2 infection and
potential factors [32]. Using a Poisson regression modelBMC Infectious Diseases 2009, 9:39 http://www.biomedcentral.com/1471-2334/9/39
Page 3 of 11
(page number not for citation purposes)
with robust variance [32], associations were first evaluated
in bivariate analysis. Covariates found to be associated
with HSV-2 assuming a threshold level of significance of
0.20 were included in the initial multivariate Poisson
regression model. The final multivariate Poisson regres-
sion model was reached by stepwise removal of covariates
not significantly associated with the outcome, starting
with the variable with the highest p-value. Covariates with
borderline association for which clinical and/or biologi-
cal relevance was assumed were kept in the final model.
Interactions identified during the modeling process were
evaluated in subsequent models; no interaction remained
in the final model. Stata Corporation for Windows, ver-
sion 7.0, was used for the statistical analyses.
Ethical approval
Written approval was obtained from the Ethics Commit-
tee of IPEC, Oswaldo Cruz Foundation, Rio de Janeiro, in
order to conduct the HSV-2 serological test on the stored
sera. This procedure complies with the National Health
Council regulation on research conducted on stored sam-
ples.
Results
The mean and median age of the 403 men was 27.5
(standard error: 7.3 years) and 26 years (interquartile
range: 18–49 years), respectively. One hundred and eighty
eight (47.2%) men reported 8 years of formal education
or less, 251 (66.6%) received 3 minimal-wages or less,
and 266 (67.3%) were working (Table 1). Only 38 (9.4%)
men reported living with a partner and 339 (84.3%)
reported being single.
One hundred and eighty one men (45.5%) self identified
themselves as MSM, while 217 (54.5%) self identified
themselves as bisexuals (Table 2). The reported age at first
sexual intercourse was less than 16 years for 272 (68.7%)
of the men (interquartile range: 12–16 years), the median
age at first sexual intercourse did not differ by the gender
of the partner. The first sexual intercourse occurred with a
woman for 307 (76.2%) of the men. Thirty eight percent
of the men reporting sex with women at least once in their
lives had their first sex act with another man. More than
half of the participants reported having a stable male part-
ner in the past six months (228, 56.6%), and, during this
period, unprotected anal sex with a stable male partner
was reported by 136 (33.7%) men. Also for the previous
six months, 267 (66.3%) men reported having an occa-
sional male partner, and, during this period, unprotected
anal sex with an occasional partner was reported by 222
(55.1%) men. Sex with a woman in the past six months
was reported by 101 (25.1%) men. Unprotected vaginal
sex with a stable and an occasional female partner was
reported by 71 (18.3%) and 51 (13.1%) men, respec-
tively. During sexual encounters happening in the past six
months, 202 (52.9%) men reported alcohol consump-
tion, while 41 (11.3%) reported cocaine use.
The point prevalence of HSV-2 was 45.7% (184 out of 403
men, 95% confidence interval: 39.3–53.7%, Table 2).
Active syphilis was detected in 31 (7.7%) men and posi-
tive serology for syphilis was detected in 140 (34.7%)
men. Positive serology for hepatitis B was detected in 134
(33.3%) men.
In the bivariate analysis (Table 3), demographic factors
most strongly associated with HSV-2 seropositivity were:
older age (≥ 26 years, PR: 1.54 95% Confidence Interval:
1.24–1.92), non-white race (PR: 1.36 95%CI: 1.09–1.70),
and living with a partner (PR: 1.41 95%CI: 1.14–1.37).
Among behavioral risk factors, younger age at first sexual
intercourse with a man (= 15 years PR: 1.28 95%CI: 1.00–
Table 1: Socio-demographic characteristics of the HIV-negative 
high-risk MSM that participated in the cross-sectional study.
Characteristic Number* (%)
Age
< 21 79 (19.6)
21–30 195 (48.4)
> 30 129 (32.0)
Race
White 205 (52.4)
Non-white 186 (47.6)
Educational level
≤ 8 years 188 (47.2)
> 8 years 210 (52.8)
Monthly income
None 50 (13.3)
1–3 minimal wages 201 (53.3)
> 3 minimal wages 126 (33.4)
Working
No 129 (32.7)
Yes 266 (67.3)
Living with
Parents or relatives 215 (53.3)
Alone 82 (20.3)
Partner 38 (9.4)
Friend 33 (8.2)
Wife and children 19 (4.7)
Others 16 (4.0)
Marital status
Single 339 (84.3)
Married 27 (6.7)
Divorced 14 (3.5)
Other 22 (5.5)
*Totals by characteristic vary because of missing values.BMC Infectious Diseases 2009, 9:39 http://www.biomedcentral.com/1471-2334/9/39
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Table 2: Behavioral characteristics and prevalence of sexually transmitted diseases among the HIV-negative high-risk MSM that 
participated in the cross-sectional study.
Characteristic Number* (%)
Sexual orientation
Homosexual 181 (45.5)
Bisexual 217 (54.5)
Age at first sexual intercourse
< 12 82 (20.7)
12–15 190 (48.0)
16–18 90 (22.7)
> 18 34 (8.6)
Age at first sexual intercourse with man
< 12 33 (13.3)
12–15 76 (30.5)
16–18 83 (33.3)
> 18 57 (22.9)
Age at first sexual intercourse with woman
< 12 16 (6.3)
12–15 120 (47.2)
16–18 87 (34.3)
> 18 31 (12.2)
First sexual intercourse with
Man 96 (23.8)
Woman 307 (76.2)
Exchange of sex for money
Never 228 (56.6)
Sometimes 175 (43.4)
Sex with a woman
Never 140 (34.7)
Sometimes 263 (65.3)
Sex with a woman in the past 6 months
Yes 101/403 (25.1)
Occasional male partner in the past 6 months
Yes 267/403 (66.3)
Stable male partner in the past 6 months
Yes 228/403 (56.6)
Unprotected anal sex with stable male partner in the past 6 months
Yes 136/403 (33.7)
Unprotected anal sex with occasional male partner in the past 6 months
Yes 222/403 (55.1)
Unprotected vaginal sex with stable female partner in the past 6 months
Yes 71/388 (18.3)
Unprotected anal sex with stable female partner in the past 6 months
Yes 34/390 (8.7)BMC Infectious Diseases 2009, 9:39 http://www.biomedcentral.com/1471-2334/9/39
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1.63), and unprotected anal sex with stable partner in the
past 6 months, irrespective of the gender of the partner
(PR: 1.20 95%CI: 0.97–1.49 for male partner and PR: 1.46
95%CI: 1.11–1.93 for female partner), were significantly
associated with HSV-2 seroprevalence. Positive serology
for syphilis (PR: 1.75 95%CI: 1.43–2.15) and hepatitis B
(PR: 1.65 95%CI: 1.33–2.05) were also significantly asso-
ciated with HSV-2 seropositivity.
In the multivariate model (Table 4), factors independ-
ently associated with HSV-2 seroprevalence were: older
age (= 26 years, PR: 1.41 95%CI: 1.11–1.78), non-white
race (PR: 1.32 95%CI: 1.06–1.64), positive serology for
syphilis (PR: 1.65 95%CI: 1.33–2.05), and hepatitis B
(PR: 1.25 95%CI: 0.99–1.57). From the behavioral factors
evaluated, those that remained independently associated
with HSV-2 seropositivity were stable male partner in the
past 6 months (PR: 1.42 95%CI: 1.12–1.79), unprotected
anal sex with a stable female partner in the 6 months pre-
ceding the baseline interview (PR: 1.46 95%CI: 1.05–
2.04).
Discussion
The present study made evident a high prevalence of HSV-
2 infection (45.7%) in this sample of HIV-negative high-
risk MSM from Rio de Janeiro. This result is consistent
with other studies conducted among MSM from other
countries and in Brazil as well [18,23,33-35]. This finding
indicates the need and urgency for implementing inte-
grated programs for the prevention of HSV-2 and other
STDs, and, in particular, programs targeting high-risk
MSM. HSV-2 is the STD most frequently associated with
the genesis of genital ulcer disease in developing coun-
tries, including Brazil [3,36,37], and is especially preva-
lent among MSM [21].
The median age of the studied population was 26 years
and chronological age was found to be independently
associated with HSV-2 infection. This finding is consistent
with published results of other investigators made within
the national and international context [4,21,34,38]. The
risk of contracting HSV-2 infection shows a practically lin-
ear increase with age [39-44], probably reflecting a higher
chance of acquiring HSV-2 given a longer exposure time
(cumulative exposure) and not an increased susceptibility
to infection as a function of age or alterations in immu-
nity as a result of aging, such as observed for other infec-
tions/diseases [16,45]. In addition, HSV-2 infection is
persistent and, therefore, no spontaneous elimination of
the virus occurs [6].
In agreement with the findings of other investigators
[1,4,20,21,40,43], non-white race was an independent
predictor of HSV-2 seropositivity. This result probably
Unprotected vaginal sex with occasional female partner in the past 6 months
Yes 51/390 (13.1)
Unprotected anal sex with occasional female partner in the past 6 months
Yes 36/389 (9.3)
Alcohol use during sexual encounter in the past 6 months
Yes 202/382 (52.9)
Cocaine use during sexual encounter in the past 6 months
Yes 41/362 (11.3)
Herpes simplex virus type 2
Yes 184/403 (45.7)
Active syphilis**
Yes 31/403 (7.7)
Positive serology for syphilis**
Yes 140/403 (34.7)
Positive serology for Hepatitis B***
Yes 134/403 (33.3)
* Totals by characteristic vary because of missing values. Totals are given next to the number for "No/Yes" dichotomous variables.
** Active syphilis implies that the antibody titer with the VDRL test was ≥ 1/8 and the TPHA was positive, while positive serology for syphilis 
implies that the VDRL test was not reactive or < 1/8 and TPHA was positive.
*** Positive serology for hepatitis B was assessed by the detection of antibodies to the hepatitis B core antigen (anti-HBC) indicating previous 
infection.
Table 2: Behavioral characteristics and prevalence of sexually transmitted diseases among the HIV-negative high-risk MSM that 
participated in the cross-sectional study. (Continued)BMC Infectious Diseases 2009, 9:39 http://www.biomedcentral.com/1471-2334/9/39
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Table 3: Factors associated with herpes simplex virus type-2 seropositivity in the bivariate analysis among the HIV-negative high-risk 
MSM that participated in the cross-sectional study.
Characteristic PR 95%CI p-value
Age
≤ 26 1.00
> 26 1.54 1.24–1.92 < 0.001
Race
White 1.00
Non-white 1.36 1.09–1.70 0.005
Educational level
≤ 8 years 1.16 0.93–1.45 0.16
> 8 years 1.00
Working
No 1.00
Yes 1.07 0.84–1.35 0.553
Living with a partner
Yes 1.41 1.14–1.37 0.001
No 1.00
Marital status
Not married 1.00
Married 1.05 0.96–1.15 0.264
Sexual orientation
Homosexual 1.00
Bisexual 1.04 0.83–1.29 0.708
Age at first sexual intercourse
≤ 15 years 1.21 0.94–1.56 0.122
> 15 years 1.00
Age at first sexual intercourse with man
≤ 15 years 1.28 1.00–1.63 0.045
> 15 years 1.00
Age at first sexual intercourse with woman
≤ 15 years 1.05 0.82–1.33 0.683
> 15 years 1.00
First sexual intercourse with
Man 1.05 0.86–1.39 0.448
Woman 1.00
Exchange of sex for money
Never 1.00
Sometimes 1.09 0.88–1.35 0.407
Sex with a woman
Never 1.00
Sometimes 1.08 0.85–1.37 0.499
Sex with a woman in the past 6 months
No 1.00
Yes 1.02 0.82–1.28 0.82BMC Infectious Diseases 2009, 9:39 http://www.biomedcentral.com/1471-2334/9/39
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relates to current or historical factors, including racial and
ethnic differences associated with poverty, access to health
services, behaviors and practices related to health in gen-
eral and to the sex and age composition of different pop-
ulation strata, and patterns of sexual behavior and
affective interaction [1,12]. The high seroprevalence
among non-whites strongly suggests that the transmission
of HSV-2 infection is influenced by factors other than
those related to individual sexual behavior, i.e. by contex-
tual and social factors as mentioned above [40].
Among the variables related to sexual behavior, stable
male partner and unprotected anal sex with stable female
partner were found associated with HSV-2 seropositivity.
Occasional male partner in the past 6 months
No 1.00
Yes 1.1 0.87–1.39 0.394
Stable male partner in the past 6 months
No 1.00
Yes 1.27 1.02–1.60 0.032
Unprotected anal sex with stable male partner in the past 6 months
No 1.00
Yes 1.2 0.97–1.49 0.088
Unprotected anal sex with occasional male partner in the past 6 months
No 1.00
Yes 0.86 0.67–1.10 0.236
Unprotected vaginal sex with stable female partner in the past 6 months
No 1.00
Yes 1.17 0.90–1.51 0.223
Unprotected anal sex with stable female partner in the past 6 months
No 1.00
Yes 1.46 1.11–1.93 0.006
Unprotected vaginal sex with occasional female partner in the past 6 months
No 1.00
Yes 0.83 0.57–1.19 0.313
Unprotected anal sex with occasional female partner in the past 6 months
No 1.00
Yes 0.7 0.43–1.12 0.142
Alcohol use during sexual encounter in the past 6 months
No 1.00
Yes 1.21 0.97–1.52 0.085
Active syphilis*
No 1.00
Yes 1.3 0.94–1.79 0.107
Positive serology for syphilis*
No 1.00
Yes 1.75 1.43–2.15 < 0.001
Hepatitis B**
No 1.00
Yes 1.65 1.33–2.05 < 0.001
* Active syphilis implies that the antibody titer with the VDRL test was ≥ 1/8 and the TPHA was positive, while positive serology for syphilis implies 
that the VDRL test was not reactive or < 1/8 and TPHA was positive.
** Positive serology for hepatitis B was assessed by the detection of antibodies to the hepatitis B core antigen (anti-HBC) indicating previous 
infection.
Table 3: Factors associated with herpes simplex virus type-2 seropositivity in the bivariate analysis among the HIV-negative high-risk 
MSM that participated in the cross-sectional study. (Continued)BMC Infectious Diseases 2009, 9:39 http://www.biomedcentral.com/1471-2334/9/39
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These findings could be related to characteristics which
are central to the transmission of HSV-2, contributing to
the cumulative risk of HSV-2 exposure, which are:
repeated exposure in stable affective relationships and the
lack of condom use in these stable relationships as repeat-
edly reported in different behavioral studies [46-48]. The
systematic use of condoms is not a common practice
among stable partners due to their proximity and inti-
macy, with protective methods often being considered as
impairment to emotional involvement and mutual trust
[46-48]. Furthermore, the characteristics of HSV-2 infec-
tion, i.e., its chronic and recurrent character [6,8], also
contribute to the lack of use of condoms (since, if there is
no supposed reason for protection, there is no motivation
for the adoption of protective measures).
In the present study, positive serology for syphilis and
hepatitis B were associated with HSV-2 seropositivity, and
remained independently associated with HSV-2 seroposi-
tivity in the multivariate model. Several studies have
shown that a history of another (hypothetically previous)
STD represents an independent predictor of HSV-2 serop-
ositivity [4,23,40,49]. Specifically with respect to syphilis,
positive serology has been independently associated with
the acquisition of HSV-2 [41]. The association with syph-
ilis may suggest a residual confounding factor in terms of
underlying sexual behaviors and/or HSV-2 infection as a
cofactor in syphilis transmission (that is, an inverse asso-
ciation). That is, although the association between HSV-2
infection and other STDs probably reflects common
behavioral risk factors, the possibility of biological inter-
actions between different infections also exists [3,12]. It is
possible that syphilis is a cofactor associated with a higher
excretion of HSV-2 or with a higher susceptibility to the
latter infection as documented for HIV infection [10].
However, in the present study the simultaneous analysis
of possible risk factors and outcomes prevents any infer-
ence regarding the direction and possible temporal
sequence of the observed associations.
It is well known that the cross-sectional analysis of data
obtained from the baseline interview of a cohort does not
allow for the establishment of causal relationships since
the reverse causality of the observed associations cannot
be ruled out (unless, of course, the reverse association is
biologically impossible). However, the central questions
of this study mainly benefit from the careful analysis of
the statistical associations as long as they are interpreted
in view of the pertinent literature.
In the present study behavioral information was obtained
through self-report. Social and psychological factors may
Table 4: Factors associated with herpes simplex virus type-2 seropositivity in the final multivariate model among the HIV-negative 
high-risk MSM that participated in the cross-sectional study.
Characteristic PR 95%CI p-value
Age
≤ 26 1.00
> 26 1.41 1.11–1.78 0.004
Race
White 1.00
Non-white 1.32 1.06–1.64 0.011
Stable male partner in the past 6 months
No 1.00
Yes 1.42 1.12–1.79 0.003
Unprotected anal sex with stable female partner in the past 6 months
No 1.00
Yes 1.46 1.05–2.04 0.023
Positive serology for syphilis*
No 1.00
Yes 1.65 1.33–2.05 < 0.001
Hepatitis B**
No 1.00
Yes 1.25 0.99–1.57 0.053
* Active syphilis implies that the antibody titer with the VDRL test was ≤ 1/8 and the TPHA was positive, while positive serology for syphilis implies 
that the VDRL test was not reactive or < 1/8 and TPHA was positive.
** Positive serology for hepatitis B was assessed by the detection of antibodies to the hepatitis B core antigen (anti-HBC) indicating previous 
infection.BMC Infectious Diseases 2009, 9:39 http://www.biomedcentral.com/1471-2334/9/39
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influence answers given to sensitive questions, such as the
sexual behavior and condom use. However, evidence sug-
gests that well-designed questionnaires provide accepta-
ble data when administered in an appropriate manner
[50]. In this study, questionnaires were applied by a study
psychologist [24].
The population of 403 men included in this study corre-
sponds to only 62% of all eligible men and the findings
therefore cannot be extrapolated to all high-risk MSM
who fulfilled the inclusion criteria of 'Projeto Rio'. More-
over, although our results are consistent with other stud-
ies conducted among MSM [33-35], our findings also do
not necessarily apply to the whole MSM population of Rio
de Janeiro or Brazil. Indeed, our population is composed
of high-risk individuals who were sought out to partici-
pate in a prospective HIV seroincidence cohort. It is possi-
ble that these first 403 men were at higher risk of HSV-2
when compared to those that later entered the study. If
this were true, our results would be over-estimating the
HSV-2 seroprevalence. In contrast, it is also possible that
the first 403 men represented an inverse selection bias,
that is, were indeed more healthy than the remaining par-
ticipants, and thus our results could be under-estimating
the HSV-2 seroprevalence. The basis for this reasoning is
the recruitment strategy of the study which sought partic-
ipants outside the health care clinic environment and
independent of clinical symptoms. That is, although the
individuals were not ill they agreed to participate in the
study, possibly indicating that they were concerned with
their health.
The present study analyzes secondary data retrospectively,
i.e., the original study was designed with other purposes
[24]. Accordingly, a more detailed investigation of specific
risk factors for HSV-2 seropositivity, such as the presence
or absence of signs or symptoms of herpes in the partner
of the participant, the number of partners the participant
had throughout life and the occurrence and duration of
herpes infection in the participant, was not possible.
However, the present study profits from the use of statisti-
cal methods tailored at the high prevalence of the event
under analysis. Although the logistic regression model
and the calculation of the respective odds ratios are the
most frequent approaches used in prevalence studies, in
the present investigation we used the Poisson regression
model since it allows for the direct estimation of the prev-
alence ratio. This is the proper approach when the basic
assumption underlying the use of logistic models, i.e., the
rarity of the event analyzed, is violated. In contrast to the
logistic regression model, which overestimates the effec-
tive prevalence ratio in these cases, the Poisson model
yields adequate estimates. Finally, it was necessary to use
a method of robust variance estimation in the application
of the Poisson model for better fit [32].
This study made evident a high seroprevalence of HSV-2
among high-risk MSM. This high seroprevalence is a mat-
ter of concern for healthcare workers and clinicians, and
represents a challenge with respect to the establishment of
preventive and control measures. The control and preven-
tion of HSV-2 infection is a growing public health concern
because of its infectivity, persistence, and role as a cofactor
in the transmission and acquisition of other STDs, includ-
ing HIV [2,3,5,6,8,10,13]. Also, the costs resulting from
HSV-2 infection are significant [11]. Acknowledgment of
the burden of HSV-2 is needed in order to appropriately
address the control and prevention of this disease and its
associated co-morbidities.
Conclusion
Seroprevalence of HSV-2 among HIV-negative high-risk
men was of 45.7%. Factors independently associated with
HSV-2 seroprevalence were: older age (= 26 years, PR: 1.41
95% CI: 1.11–1.78), non-white race (PR: 1.32 95%CI:
1.06–1.64), positive serology for syphilis (PR: 1.65
95%CI: 1.33–2.05), positive serology for hepatitis B (PR:
1.25 95%CI: 0.99–1.57), stable male partner in the past 6
months (PR: 1.42 95%CI: 1.12–1.79), and unprotected
anal sex with a stable female partner (PR: 1.46 95%CI:
1.05–2.04) in the 6 months preceding the cross-sectional
assessment.
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